New drug combo may boost prostate cancer surgery success

NCT ID NCT05826509

Ongoing Disease control Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the drug darolutamide before and after surgery helps men with high-risk or locally advanced prostate cancer. About 240 men will either have surgery alone or surgery plus the drug. The goal is to see if the drug delays the cancer from coming back or spreading.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

CHU Bordeaux

Bordeaux, France
CHU Grenoble

Grenoble, France
CHU Lyon - Hôpital Edouard Herriot

Lyon, France
CHU Lyon - Sud

Pierre-Bénite, France
CHU Rennes

Rennes, France
CHU Toulouse

Toulouse, France
Chu Angers

Angers, France
Chu Henri Mondor

Créteil, France
Chu Tours - Hopital Bretonneau

Tours, France
Clinique La Croix Du Sud

Quint-Fonsegrives, France
Hopital Claude Huriez

Lille, France
Hopital Europeen Georges-Pompidou

Paris, France
Hopital Foch

Suresnes, France
Hopital Paris Saint-Joseph

Paris, 75014, France
Hopital Pitie Salpetriere

Paris, France
Institut Bergonié

Bordeaux, France
Institut Mutualiste Montsouris

Paris, France
Institut Paoli-Calmettes

Marseille, France
Institut Universitaire Du Cancer Toulouse - Oncopole

Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.